C
Carlos Cordon-Cardo
Researcher at Icahn School of Medicine at Mount Sinai
Publications - 620
Citations - 91832
Carlos Cordon-Cardo is an academic researcher from Icahn School of Medicine at Mount Sinai. The author has contributed to research in topics: Cancer & Prostate cancer. The author has an hindex of 144, co-authored 589 publications receiving 84862 citations. Previous affiliations of Carlos Cordon-Cardo include The Rogosin Institute & Erasmus University Rotterdam.
Papers
More filters
Journal ArticleDOI
p53 and RB: Simple Interesting Correlates or Tumor Markers of Critical Predictive Nature?
TL;DR: Chatterjee et al. as mentioned in this paper found that the number of altered proteins remained significantly correlated with both time to recurrence and overall survival in patients with bladder cancer, and that these proteins were independent predictors of both time-to-reaction and overall survivability.
Journal ArticleDOI
PI3K/AKT pathway regulates E-cadherin and Desmoglein 2 in aggressive prostate cancer.
Alison G. Barber,Mireia Castillo-Martin,Dennis M. Bonal,Angela J. Jia,Angela J. Jia,Benjamin A. Rybicki,Angela M. Christiano,Carlos Cordon-Cardo +7 more
TL;DR: Findings illustrate the critical role of cell–cell adhesion in the progression to aggressive prostate cancer, through regulation by the PI3K pathway.
Journal Article
Immunopathologic analysis of human urinary bladder cancer. Characterization of two new antigens associated with low-grade superficial bladder tumors.
TL;DR: The normal human tissue distribution and tumor expression of two highly restricted tumor-associated antigens, detected by mouse monoclonal antibodies M344 and 19A211, which are primarily expressed on low-grade superficial urinary bladder tumors are characterized.
Journal ArticleDOI
TSPYL2 is an essential component of the REST/NRSF transcriptional complex for TGFβ signaling activation.
Mirjam T. Epping,Andrea Lunardi,D Nachmani,Mireia Castillo-Martin,Tin Htwe Thin,Carlos Cordon-Cardo,Pier Paolo Pandolfi +6 more
TL;DR: It is demonstrated that the TSPYL2/REST complex promotes TGFβ signaling by repressing the expression of genes, such as the proto-oncogene neurotrophic tyrosine kinase receptor C (TrkC), which provides insight into the role of REST as a tumor suppressor in epithelial tissues through the regulation of the TGF β pathway.
Journal ArticleDOI
A comparison of the outcomes of neoadjuvant and adjuvant chemotherapy for clinical T2-T4aN0-N2M0 bladder cancer
Matthew S. Wosnitzer,Gregory W. Hruby,Alana M. Murphy,LaMont J. Barlow,Carlos Cordon-Cardo,Mahesh M. Mansukhani,Daniel P. Petrylak,Mitchell C. Benson,James M. McKiernan +8 more
TL;DR: Patient outcomes following neoadjuvant or adjuvant systemic chemotherapy for cT2‐T4aN0‐N2M0 bladder cancer is compared.